| Today's Big NewsJun 14, 2023 |
| By Gabrielle Masson After nearly 20 years away, pharma vet Paul Burton, M.D., Ph.D., is returning to Amgen. The leader will leave his chief medical officer spot at Moderna for the same role at Amgen. |
|
|
|
By Kevin Dunleavy An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. A month later, according to an SEC filing, Pfizer has withdrawn its notification for its proposed $43 billion acquisition of cancer drug specialist Seagen and will submit another later in the day. |
By Nick Paul Taylor Investigators have paused an early-phase trial of 2seventy bio’s CD33-targeted CAR-T cell therapy after a patient died. The acute myeloid leukemia (AML) patient was the first person treated in the second dose cohort of the phase 1 clinical trial. |
By Zoey Becker Sanofi's new app, plai, provides teams with a “360° view" to aid decision-making. The platform is one step in the company's digital transformation and goal to become the "first pharma powered by AI at scale." |
|
Wednesday, June 28, 2023 11:00am ET / 8:00am PT Join us for this this insightful webinar to learn how antibody profiling has been used to successfully identify novel diagnostic, prognostic, therapeutic, and predictive biomarkers in melanoma, prostate cancer, breast cancer, ovarian cancer, and rare cancers, yielding promising results.
|
|
By Helen Floersh Brain aneurysms at risk of rupture can only be treated with surgery, and that may not be possible if the aneurysm is in a hard-to-access location. But a new study hints at another solution: the cancer drug sunitinib, commercialized by Pfizer as Sutent, which appears to prevent aneurysms in mice. |
By Zoey Becker As supply chain issues sweep across the industry, Pfizer is warning about expected supply shortfalls of its penicillin offerings. |
By Max Bayer Merck says its GLP-1/glucagon receptor co-agonist has the upper hand against Ozempic in patients with NASH, according to abstract data from a phase 2a trial. The New Jersey Big Pharma plans to present a fuller look at the data at the European Association for the Study of the Liver annual congress. |
By Angus Liu Remember how bluebird bio retreated from Europe after failing to reach reimbursement deals for its gene therapies? Now, one team of analysts believes BioMarin’s hemophilia A gene therapy, Roctavian, may have big potential in the market if the company can overcome the reimbursement hurdle. |
By James Waldron Fresh from Qalsody’s success, Biogen is keeping its eye on whether a candidate from NeuroSense Therapeutics could also prove to be a hit against the same biomarker—and maybe become the next addition to the Big Pharma’s amyotrophic lateral sclerosis portfolio. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the the top news from this year's annual ASCO meeting, plus contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. |
|
|---|
|
|
|
Monday, June 26, 2023 | 11:00 am ET Join us for a webinar on “The RESTORE Trial: First-Ever Lab-Grown RBCs” where Dr. Ashley Toye will talk about the first-ever clinical trial conducted for the transfusion of lab-grown red blood cells. Register now. |
|
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| |
|
